DarioHealth Corp. (DRIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153039,
    "name": "DarioHealth Corp.",
    "stock_name": "DarioHealth Corp.",
    "full_name": "DarioHealth Corp.",
    "name_url": "stocks-analysis/dariohealth-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "12.05",
    "chg": 0.16,
    "chgp": "1.35%",
    "dir": 1,
    "prev_price": "11.89",
    "mcapval": "22.08",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US23725P2092",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "21.33 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dariohealth-corp-1153039-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is DarioHealth Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dariohealth-corp-technically-bullish-or-bearish-3546086",
        "imagepath": "",
        "date": "2025-09-20 19:24:36",
        "description": "As of 8 September 2025, the technical trend for DarioHealth Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the monthly MACD and KST indicators, which are both mildly bullish. However, the weekly MACD, Bollinger Bands, and Dow Theory indicate bearish conditions, suggesting a mixed outlook. The daily moving averages are also bearish, adding to the overall caution. \n\nIn terms of performance, DarioHealth has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -60.76% compared to the S&P 500's 12.22%, and a one-year return of -65.72% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is DarioHealth Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dariohealth-corp-overvalued-or-undervalued-3542712",
        "imagepath": "",
        "date": "2025-09-20 18:00:06",
        "description": "As of 11 May 2016, the valuation grade for DarioHealth Corp. changed from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses and negative valuation metrics. Key ratios include a Price to Book Value of 0.42, an EV to EBIT of -0.67, and an EV to EBITDA of -0.80, all of which reflect a concerning financial position.\n\nIn comparison to peers, DarioHealth Corp. has a less favorable EV to EBITDA ratio than Clearpoint Neuro, Inc. (-14.42) and Stereotaxis, Inc. (-11.42), both of which are also classified as risky but show less severe negative metrics. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -60.76% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued...."
      },
      {
        "title": "DarioHealth Corp. Stock Plummets to New 52-Week Low of $6.00",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dariohealth-corp-stock-plummets-to-new-52-week-low-of-600-3525837",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/DarioHealthCorp_priceRelatedfactors_3525837.png",
        "date": "2025-09-17 15:15:45",
        "description": "DarioHealth Corp. has reached a new 52-week low of USD 6.00, despite a remarkable one-year performance of 372.52%. The company faces challenges with negative EBITDA and a return on equity of -53.24%, while maintaining a market capitalization of USD 22 million and a low debt-to-equity ratio."
      },
      {
        "title": "DarioHealth Corp. Hits New 52-Week Low at $6.58 Amid Financial Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dariohealth-corp-hits-new-52-week-low-at-658-amid-financial-concerns-3519589",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/DarioHealthCorp_priceRelatedfactors_3519589.png",
        "date": "2025-09-16 11:23:55",
        "description": "DarioHealth Corp. has reached a new 52-week low, reflecting significant stock volatility despite a strong one-year performance. The company, with a market capitalization of USD 22 million, faces challenges including negative return on equity and EBITDA, while maintaining a low debt-to-equity ratio, highlighting its financial complexities."
      }
    ],
    "total": 9,
    "sid": "1153039",
    "stock_news_url": "https://www.marketsmojo.com/news/dariohealth-corp-1153039"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is DarioHealth Corp. technically bullish or bearish?

2025-09-20 19:24:36

As of 8 September 2025, the technical trend for DarioHealth Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the monthly MACD and KST indicators, which are both mildly bullish. However, the weekly MACD, Bollinger Bands, and Dow Theory indicate bearish conditions, suggesting a mixed outlook. The daily moving averages are also bearish, adding to the overall caution. In terms of performance, DarioHealth has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -60.76% compared to the S&P 500's 12.22%, and a one-year return of -65.72% versus the S&P 500's 17.14%....

Is DarioHealth Corp. overvalued or undervalued?

2025-09-20 18:00:06

As of 11 May 2016, the valuation grade for DarioHealth Corp. changed from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses and negative valuation metrics. Key ratios include a Price to Book Value of 0.42, an EV to EBIT of -0.67, and an EV to EBITDA of -0.80, all of which reflect a concerning financial position. In comparison to peers, DarioHealth Corp. has a less favorable EV to EBITDA ratio than Clearpoint Neuro, Inc. (-14.42) and Stereotaxis, Inc. (-11.42), both of which are also classified as risky but show less severe negative metrics. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -60.76% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued....

DarioHealth Corp. Stock Plummets to New 52-Week Low of $6.00

2025-09-17 15:15:45

DarioHealth Corp. has reached a new 52-week low of USD 6.00, despite a remarkable one-year performance of 372.52%. The company faces challenges with negative EBITDA and a return on equity of -53.24%, while maintaining a market capitalization of USD 22 million and a low debt-to-equity ratio.

DarioHealth Corp. Hits New 52-Week Low at $6.58 Amid Financial Concerns

2025-09-16 11:23:55

DarioHealth Corp. has reached a new 52-week low, reflecting significant stock volatility despite a strong one-year performance. The company, with a market capitalization of USD 22 million, faces challenges including negative return on equity and EBITDA, while maintaining a low debt-to-equity ratio, highlighting its financial complexities.

View All News